Carboplatin + Etoposide

Indication

Extensive stage

Regimen 1

• Carboplatin 300 mg/m2 iv d1
• Etoposide (VP-16) 100 mg/m2/d iv d1-3
• Q4w x 4 cycles

References

Smith IE et al. Carboplatin (paraplatin; JM8) and etoposide (VP16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 1987; 5:185

Regimen 2

• Carboplatin AUC 5 iv d1
• Etoposide (VP-16) 100 mg/m2/d iv d1-3
• Q4w x 6 cycles

References

Quoix E et al. Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. Ann Oncol 2001; 12:957

Regimen 3

• Carboplatin AUC 5 iv over 1 h d1
• Etoposide (VP-16) 140 mg/m2/d iv over 90 min d1-3
• Q3w

References

Schmittel A et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006; 17:663

Regimen 4

• Carboplatin AUC 5 iv d1
• Etoposide (VP-16) 80 mg/m2/d iv d1-3
• Filgrastim (Neupogen) support
• Q3-4 w x 4 cycles

References

Okamoto H et al. Randomized phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007; 97:162